Why Meridian Bioscience Is Poised to Outperform
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, diagnostic test maker Meridian Bioscience has earned a coveted five-star ranking.
With that in mind, let's take a closer look at Meridian and see what CAPS investors are saying about the stock right now.
Meridian facts
Headquarters (founded) | Cincinnati (1976) |
Market Cap | $886.4 million |
Industry | Healthcare supplies |
Trailing-12-Month Revenue | $173.5 million |
Management | CEO John Kraeutler (since 2008) |
Return on Equity (average, past 3 years) | 20.9% |
Cash/Debt | $31.6 million / $0 |
Dividend Yield | 3.6% |
Competitors | Abbott Labs |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 97%of the 475 members who have rated Meridian believe the stock will outperform the S&P 500 going forward.
A few months ago, one of those Fools, TempAllegro, succinctly summed up the bull case for our community:
[Meridian] makes a range of diagnostic tests for foodborne, parasitic, viral, and other diseases that you can do at home. ...
With increasing threats to the food supply and environmental concerns such as lack of proper water for both humans and livestock, these tests will be both helpful and in greater demand in coming years.
Add to that its great balance sheet -- currently with zero debt and current ratio of over 5, plus high insider ownership, generous dividend, and 5-year projected growth in the mid-teens, and we have an excellent addition to anyone's health-oriented portfolio.
If you want market-thumping returns, you need to put together the best portfolio you can. Of course, despite a strong four-star rating, Meridian may not be your top choice.
We've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2013." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
The article Why Meridian Bioscience Is Poised to Outperform originally appeared on Fool.com.
Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool recommends Becton Dickinson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
